Furukawa Masaru, Ishii Yasutaka, Serikawa Masahiro, Tsuboi Tomofumi, Tatsukawa Yumiko, Hirano Tetsuro, Nakamura Shinya, Ikemoto Juri, Kiyoshita Yusuke, Saeki Sho, Tamura Yosuke, Miyamoto Sayaka, Nakamura Kazuki, Yamashita Yumiko, Iijima Noriaki, Uemura Kenichiro, Oka Shiro
Department of Gastroenterology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8551, Japan.
Department of Surgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8551, Japan.
J Clin Med. 2023 Sep 28;12(19):6245. doi: 10.3390/jcm12196245.
We aimed to compare the utility of covered self-expanding metal stents (CSEMSs) with that of plastic stents (PSs) for biliary drainage during neoadjuvant chemotherapy in patients with borderline resectable pancreatic cancer.
Forty patients with borderline resectable pancreatic cancer underwent biliary stenting during neoadjuvant chemotherapy at Hiroshima University Hospital. PSs and CSEMSs were placed in 19 and 21 patients, respectively. Two gemcitabine-based regimens for chemotherapy were used. Treatment outcomes and postoperative complications were compared between both groups.
The incidence of recurrent biliary obstruction was significantly lower in the CSEMS group (0% vs. 47.4%, < 0.001), and the median time to recurrent biliary obstruction in the PS group was 47 days. There was no difference in the incidence of other complications such as non-occlusive cholangitis, pancreatitis, and cholecystitis between the two groups. Delays in the chemotherapy schedule due to stent-related complications were significantly frequent in the PS group (52.6% vs. 4.8%, = 0.001). There was no significant difference in the incidence of postoperative complications between the two groups.
CSEMSs may be the best choice for safely performing neoadjuvant chemotherapy for several months in patients with borderline resectable pancreatic cancer with bile duct stricture.
我们旨在比较覆膜自膨式金属支架(CSEMS)与塑料支架(PS)在新辅助化疗期间用于临界可切除胰腺癌患者胆道引流的效用。
40例临界可切除胰腺癌患者在广岛大学医院新辅助化疗期间接受了胆道支架置入术。PS和CSEMS分别置入19例和21例患者。使用了两种基于吉西他滨的化疗方案。比较两组的治疗结果和术后并发症。
CSEMS组复发性胆道梗阻的发生率显著较低(0%对47.4%,<0.001),PS组复发性胆道梗阻的中位时间为47天。两组之间其他并发症如非闭塞性胆管炎、胰腺炎和胆囊炎的发生率没有差异。PS组因支架相关并发症导致化疗计划延迟的情况明显更频繁(52.6%对4.8%,=0.001)。两组术后并发症的发生率没有显著差异。
对于伴有胆管狭窄的临界可切除胰腺癌患者,CSEMS可能是安全进行数月新辅助化疗的最佳选择。